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Hypertrophic cardiomyopathy (HCM) is a major cause of
premature sudden death in the young, a fact made all the
more unsettling to affected families and physicians by the
frequent absence of symptoms prior to death (1). Published
annual sudden death rates have varied as a function of the
patient selection and management, with values prior to the
use of prophylactic implantable cardioverter-defibrillators
(ICD) for children and adolescents of 3% to 6%, and 0.5%
to 1.0% in adults. The motivation to increase efforts to
identify high-risk patients has been greatly stimulated by
the growing recognition that the ICD is highly effective in
primary and secondary prevention of sudden cardiac death
in HCM (2).
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Clinically, HCM is defined and diagnosed by the dem-
onstration of unexplained left ventricular hypertrophy
(LVH). Mutations in eight different sarcomeric contractile
protein genes (beta myosin heavy chain [MYH7], troponin
T [TNNT2], alpha tropomyosin [TPM1], myosin binding
protein C [MYBPC3], regulatory myosin light chain
[MYL2], essential myosin light chain [MYL3], troponin I
[TNNI3] and alpha cardiac actin [ACTC] have been shown
to cause disease; mutations in the titin, alpha heavy chain
myosin and troponin C genes have also been described (3).
Preliminary genotype-phenotype studies have suggested
that some mutations may be associated with a high inci-
dence of disease-related mortality, whereas others appear to
have a more “benign” course (4). This has led to the
attractive hypothesis that genotyping may facilitate identi-
fication of individuals at high risk of sudden cardiac death
(5).
In this issue of the Journal, Ackerman et al. (5) from the
Mayo Clinic examine the prevalence in a population of 293
patients of several mutations (four MYH7: R403Q [exon
13], R453C [exon 14], G716R and R719W [exon 19], and
one TNNT2 mutation: R92W [exon 9]), which have
previously been associated with premature sudden cardiac
death. Fifty-three percent of the study cohort, approxi-
mately twice the proportion of patients seen in most referral
centers, had symptoms associated with left ventricular (LV)
outflow tract obstruction, reflecting the well-recognized
surgical expertise of the Mayo Clinic. Although the risk
profile of the cohort was not presented in detail with regard
to syncopal episodes, nonsustained ventricular tachycardia
(NSVT) on Holter, or abnormal blood pressure response
during upright exercise, 24% were recorded to have a family
history of at least one sudden cardiac death prior to age 40,
6% had extreme hypertrophy (maximum LV wall thickness
30 mm) and 8.5% had received an ICD. These propor-
tions and other demographics such as age, symptoms and
LV morphology are similar to those seen in other referral
centers.
Ackerman et al. (5) found a malignant mutation in only
3 (1%) of the 293 patients. They conclude that given the low
prevalence of “malignant” MYH7 and TNNT2 mutations
in a tertiary center, genetic testing is unlikely to contribute
significantly to risk assessment. This view is supported by a
number of additional considerations, in particular the ob-
servation that even within so-called high risk families, there
is variable disease expression and prognosis, probably re-
flecting the influence of other genetic and environmental
factors on gene expression. For example, a large Scottish
family with an exon 15 splice site mutation in TNNT2 in
which eight individuals died suddenly age 30 years (six as
teenagers) whereas eight other affected individuals survived
into their seventh or eighth decade (4). This variability is
also illustrated by a number of reported exceptions to many
of the proposed genotype-phenotype associations, although
these may reflect factors such as the size of the families
studied, the failure to consider the influence of effective
prophylactic treatment and the confounding presence of a
second disease causing mutation. A limitation of the ap-
proach taken in the Ackerman et al. (5) study was that there
must have been other “malignant” mutations that were
impossible to assess because of our current limited state of
knowledge and genotyping capacity. The fact that for
several of the disease genes (MYH7, MYBPC3), individual
families have their own private mutations will also continue
to represent an obstacle.
If genotyping is currently problematic in prognostic
assessment, can clinical evaluation identify the high-risk
patient? Over the past four decades, a number of clinical
features have been proposed as markers of sudden death risk
in patients with hypertrophic cardiomyopathy. Their appli-
cation in clinical practice has, however, remained unsystem-
atic and haphazard, reflecting not only perceived doubts
about the predictive value of individual risk markers, but
also a number of misconceptions about the natural history of
the disease. The latter have been exacerbated by what seem
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to be contradictory survival studies demonstrating both
prognosis that differs little from that seen in age-matched
controls and others that report increases in risk sufficient to
warrant aggressive prophylactic antiarrhythmic treatment in
anyone with one of a number of “adverse” clinical manifes-
tations. This apparent paradox is exemplified by the recent
debate on the clinical significance of extreme LVH in HCM
(6,7). Several studies have shown that patients with a
maximum LV wall thickness of 30 mm have an increased
risk of dying suddenly, a finding that some authorities
suggest is sufficient to warrant consideration of an ICD in
any patient with “extreme” hypertrophy. Unfortunately, at
least 10% of patients in most of the published survival
studies have an LV wall thickness of 30 mm. Moreover,
the majority of sudden deaths occur in patients with a wall
thickness of 30 mm. Reliance on hypertrophy alone
would, therefore, fail to prevent the majority of HCM-
related sudden deaths.
The fundamental problem with most proposed clinical
risk markers is that, individually, they are at best only
modestly predictive of short- to medium-term risk of
sudden death (8). Many cardiologists have, as a conse-
quence, treated patients in reaction to events such as the
sudden death of a sibling or an episode of unexplained
syncope. Although this policy is understandable given the
often emotive context, clinical and genetic studies suggest
that it may not always be necessary. Despite clinical expe-
rience suggesting that adverse family history and syncope
are harbingers of future events in some individual circum-
stances, most statistical analyses of outcome in large series
indicate that they are no more predictive of sudden death
risk than other less routinely determined and less dramatic
clinical markers (e.g., NSVT on Holter, abnormal exercise
blood pressure response). In the case of syncope, this is not
particularly surprising given the many different mechanisms
that may cause a patient with HCM to faint. Similarly, the
highly variable natural history in patients with the same
mutation indicates that family history by itself is unlikely to
be a reliable guide to an individual patient’s risk of sudden
death.
Clinically, the easiest high-risk group to define are those
patients who have already declared their propensity for fatal
ventricular arrhythmia by surviving an episode of sustained
ventricular tachycardia or ventricular fibrillation. These
patients have a 5% to 11% chance of a further event in five
years; given the proven efficacy of ICDs in this group, they
should be treated aggressively (2). At the other extreme,
most experts would agree that asymptomatic patients with
mild hypertrophy (2 cm), a normal exercise blood pressure
response, an absence of arrhythmia on Holter and exercise
testing and with no family history of premature sudden
death have a very low risk of sudden death and can, in the
main, be reassured.
To guide decision making in the remainder of patients,
we have recently proposed that patients should be “strati-
fied” using a careful but relatively simple assessment that in
addition to clinical and family history includes exercise
testing, Holter monitoring and echocardiography (8). In a
prospective study of a consecutively referred population,
patients with two or more risk markers (a history of
unexplained syncope, a family history of premature sudden
deaths, an abnormal exercise blood pressure response,
NSVT, or massive LVH) had an annual sudden death risk
of at least 3%, suggesting that noninvasive clinical assess-
ment alone can be used to identify a cohort of patients who
might benefit from ICD implantation (8). It is clear that
risk stratification remains a challenge in particular sub-
groups of patients—for example, the young and patients
who have only a single “risk factor.” When advising indi-
vidual patients on their risk, the clinical assessment has also
to take into account factors such as age, evidence of ischemia
and additional details related to the risk marker, which,
though important, have been difficult to factor in to statistical
analysis. The complexity of the risk assessment does not,
however, negate the process itself, and in experienced hands
most high-risk patients can be identified prospectively.
Does genotyping have a future role in guiding risk-factor
stratification? The concept of a malignant versus benign
mutation, which underpinned the Ackerman et al. study (5),
assumes some degree of homogeneity of patients with the
same mutation. Similarly, the current approach to clinical
risk-factor assessment assumes patients with the same risk
markers have a similar risk of sudden death. Nevertheless
it is probable that future studies will confirm the original
hypothesis in Ackerman et al. (5) that selected MYH7 and
TNNT2 mutations do confer an increased risk of disease-
related complications. At present, the clinician does not
have genotyping available as a routine clinical test and must
consider an HCM patient under the broad umbrella of
“unexplained LVH.”
Finally, preliminary genotype-phenotype studies suggest
differences between the disease-causing genes with respect
to penetrance, age of expression, as well as morphology and
prognostic severity (3,4). In the future, HCM may be
considered as eight or more different but related heart-
muscle disorders with a differing pathogenesis and, impor-
tantly, a different risk-factor profile. Whether the attractive
concept of benign versus malignant mutations is sustainable
is uncertain, but knowledge of the underlying genotype
should set the framework for both symptomatic and risk
management strategies.
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